MapLight Therapeutics, Inc. 8-K

What Happened MapLight Therapeutics, Inc. filed an 8-K (Item 5.02) reporting that on April 23, 2026 directors Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board they will not stand for reelection at the Company’s Annual Meeting of Stockholders scheduled for June 23, 2026. The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle. The filing states both departures were not due to any disagreement with the Company on matters relating to operations, policies, or practices.

Key Details

• Notification date: April 23, 2026.
• Departing directors: Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D.
• Nominees named: Martin Babler and Troy Cox as Class I director nominees.
• Annual Meeting date: June 23, 2026; departures are for the upcoming election cycle and are described as non-disputative.

Why It Matters Board membership changes affect corporate governance and who will oversee strategy and management. These are voluntary, non-dispute departures and the Board has already nominated replacements, suggesting an orderly transition. Investors should note the upcoming vote at the June 23, 2026 Annual Meeting to confirm the new directors.